Remove Compliance Remove Life Science Remove Pharma Companies Remove Regulation
article thumbnail

Lay of the land: Understanding lay summary requirements and the challenges they bring

Pharmaceutical Technology

Designed to explain either the risk management plan (RMP) or clinical trial results (CTR) in a way that a child can understand, lay summaries are now a required document for all clinical trials in the European Union (EU) following changes to EU Clinical Trials Regulations (EU-CTR) regulations earlier this year.

article thumbnail

Amplifying HCP engagement using modular content

pharmaphorum

Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in life sciences, and rightly so because HCPs’ needs and expectations have changed. “There isn’t a one-size-fits-all for how the life sciences industry creates content.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

article thumbnail

Clinical Data Management Experts Share Insights on Modern Digital Clinical Trials

XTalks

They discussed current challenges and solutions that life science companies and clinical development organizations have with the management of clinical data. To produce ethical results in a timely manner, life science companies should ensure that they have a robust and reliable clinical data pipeline in place.

article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

article thumbnail

Hollywood and the Metaverse’s effect on pharma’s content

pharmaphorum

Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharma companies’ customer communication methods require reimagining as technology progresses. About the author.

Branding 113
article thumbnail

How digital is transforming the commercial leader’s role in biopharma

pharmaphorum

To compete now, companies need to own a larger portion of the treatment journey and the overall patient care experience. Commercial leaders should leverage the internal capabilities and centres of excellence that pharma companies are increasingly building. About BrightInsight.

Marketing 132